SCHEMBL30526106

SCHEMBL30526106

COc1ccc(CN2C=C(c3cc(C(F)(F)F)nc(S(C)(=O)=O)n3)C=CC2)cc1OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SDHB P21912 14/20 0.59
▸ NPSR1 Q6W5P4 6/20 0.56
▸ HPGD P15428 5/20 0.56
▸ HTT P42858 4/20 0.56
▸ LMNA P02545 4/20 0.56
▸ TP53 P04637 4/20 0.56
▸ SMN1; SMN2 Q16637 4/20 0.56
▸ KMT2A Q03164 3/20 0.56
▸ HSD17B10 Q99714 3/20 0.56
▸ KDM4E B2RXH2 4/20 0.48
▸ STAT3 P40763 4/20 0.48
▸ MITF O75030 2/20 0.48
▸ ALDH1A1 P00352 3/20 0.45
▸ USP2 O75604 1/20 0.45
▸ RAB9A P51151 3/20 0.41
▸ STAT1 P42224 2/20 0.41
▸ TLR9 Q9NR96 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ S1PR4 O95977 1/20 0.41
▸ POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28307462 1.00 SDHB (0.59) SDHBNPSR1HPGDHTTLMNA
SCHEMBL28307452 0.90 SDHB (0.48) SDHBNPSR1HPGDHTTLMNA
SCHEMBL28306261 0.89 SDHB (0.58) SDHBNPSR1HPGDHTTLMNA
SCHEMBL28307460 0.88 SDHB (0.45) SDHBNPSR1HPGDHTTLMNA
SCHEMBL28307434 0.88 SDHB (0.63) SDHBNPSR1HPGDHTTLMNA
SCHEMBL28306444 0.87 SDHB (0.54) SDHBNPSR1HPGDHTTLMNA
SCHEMBL28306456 0.87 SDHB (0.64) SDHBNPSR1HPGDHTTLMNA
SCHEMBL28306448 0.87 SDHB (0.60) SDHBNPSR1HPGDHTTLMNA
SCHEMBL28307457 0.86 SDHB (0.56) SDHBNPSR1HPGDHTTLMNA
SCHEMBL28307456 0.86 SDHB (0.43) SDHBNPSR1HPGDHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250210201-A1 METHODS FOR STRATIFICATION OF PARKINSON'S DISEASE PATIENTS, SYSTEMS AND USES THEREOF UNIV LUXEMBOURG (LU) 2025-06-26 — — US disclosed
EP-4493725-A1 METHODS FOR STRATIFICATION OF PARKINSON'S DISEASE PATIENTS, SYSTEMS AND USES THEREOF Université du Luxembourg (LU) 2025-01-22 — — EP disclosed
WO-2023174989-A1 METHODS FOR STRATIFICATION OF PARKINSON'S DISEASE PATIENTS, SYSTEMS AND USES THEREOF UNIVERSITÉ DU LUXEMBOURG (LU) 2023-09-21 — — WO disclosed
US-11725000-B2 Apoptosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-08-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11725000-B2 Apoptosis inhibitors BAX, SDHA, SDHB SDHB 3/4885NPSR1 4745/4885HPGD 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback